PATENT
Customer No. 22,852
Attorney Docket No. **10577.0004-00000**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	)	
Yasuaki ITO et al.	)	Group Art Unit: 1646
	)	
Application No.: 10/542,408	)	Examiner: Zachary C. HOWARD
	)	
371(c) Date: July 15, 2005	)	Confirmation No.: 8596
I.A. Filing Date: January 15, 2004	)	
	)	
For: NOVEL SCREENING METHOD	)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

Applicants now respond to the Restriction Requirement mailed September 28, 2009. The period for reply has been extended to November 28, 2009, by the Petition for One Month Extension of Time and fee payment filed herewith.

Restriction Requirement

The Office required restriction to one of the following groups of claims under 35 U.S.C. §§ 121 and 372:

Group I	Claims 1, 3, 14, and 67-70, allegedly "drawn to a method of screening for a compound that modulates binding of a receptor to a fatty acid comprising using said receptor and fatty acid, or to a method for confirming that a drug binds to said receptor."
Group II	Claims 2 and 4, allegedly "drawn to kits comprising a receptor and a fatty acid that binds said receptor, and kits comprising a receptor and a compound that modulates binding of said receptor and fatty acid."
Group III	Claims 5-13, 15-18, and 45-50, allegedly "drawn to an agent comprising a compound that modulates the binding of a receptor and a fatty acid."

Group IV	Claims 19-25, 33-36, and 73-77, allegedly "drawn to a polynucleotide encoding a GPCR or a complement of said polynucleotide, vectors and cells comprising said GPCR, and a method of producing said GPCR using a host cell transformed with a vector."
Group V	Claims 26-32, allegedly "drawn to an antibody that binds to a GPCR."
Group VI	Claims 37-40, allegedly "drawn to an agent that increases the expression level of a GPCR."
Group VII	Claims 41-44, allegedly "drawn to an agent comprising a compound that decreases the expression level of a GPCR."
Group VIII	Claims 51-54, "in so far as they are drawn to a method of treatment comprising administering a GPCR."
Group IX	Claims 51-58, "in so far as they are drawn to a method of treatment comprising administering a polynucleotide encoding a GPCR."
Group X	Claims 51-54, "in so far as they are drawn to a method of treatment comprising administering an agonist of a GPCR."
Group XI	Claims 55-58, "in so far as they are drawn to a method of treatment comprising administering an antagonist of a GPCR."
Group XII	Claim 71, allegedly "drawn to a pharmaceutical comprising the combination of an agonist or antagonist to a GPCR, and/or a compound that changes the expression level of said GPCR, and/or a drug."
Group XIII	Claim 72, allegedly "drawn to an isolated GPCR consisting of SEQ ID NO: 8."

Applicants elect Group I, claims 1, 3, 14, and 67-70, without traverse.

In addition to an election of groups, the Examiner requires two elections of species, as set forth below.

The first species election relates to the species of GPCR, namely:

1) SEQ ID NO. 1 (Human);

2) SEQ ID NO: 2 (Mouse); and

3) SEQ ID NO 8 (Rat).

Applicants elect the species 1) SEQ ID NO. 1 (Human). At least claims 1, 3, 14, and 67-70 read on the elected species.

The second species election relates to a disorder, namely:

> diabetes mellitus, hyperlipemia, arteriosclerosis, angina pectoris, myocardial infarction, stress, Cushing's disease, infectious disease, secondary adrenocortical insufficiency, peptic ulcer, diabetes mellitus, mental disorder, cataract, glaucoma, tuberculous disease, hypertension, Cushing's syndrome, adrenocortical atrophy, obesity, rheumatism, systemic lupus erythematosus, polymyositis, rheumatic fever, scleroderma, kidney disease, bronchial asthma, pulmonary tuberculous pleuritis, sarcoidosis, diffuse interstitial pneumonia, ulcerative colitis, cholestatic acute hepatitis, fulminant hepatitis, chronic hepatitis, cirrhosis, encephalomyelitis, peripheral neuritis, multiple sclerosis, myasthenia gravis, facial paralysis, hemolytic anemia, granulocytosis, purpura, aplastic anemia, leukemia, malignant lymphoma, acute or chronic adreno-cortical insufficiency, adrenogenital syndrome, malignant exopthalmos due to thyroid gland disease, ACTH isolated deficiency, urticaria, eczema, dermatitis, herpes zoster, psoriasis, drug allergy, anaphylactic shock, impaired glucose tolerance, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, hyperlipemia, arteriosclerosis, angina pectoris, myocardial infarction, sexual dysfunction, obesity, pituitary dysfunction, cancer, deficits in memory and learning, pancreatic exhaustion, hypoglycemia, insulin allergy, lipotoxicity, fatty atrophy, cancerous cachexia, hyper-insulinemia, hyperglycemia, disorder caused by high FFA flux, hypertriglyceridemia, fatty liver, dysfunction of heat production, cholelithiasis,

eating disorder, secretion disorders of intestinal hormones, circulatory disease and ACTH-producing tumor.

Applicants elect the species of diabetes mellitus. At least claims 1, 3, 14, 67, 68, and 70 read on the elected species.

Applicants note that if the Office finds that the elected species is patentable, it is required to examine the other species.

Please grant any extensions of time required to enter this response, and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: November 23, 2009

By: Jean Burke Fordis

Jean Burke Fordis
Reg. No. 32,984
Customer No. 22,852